Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERACYTE, INC.VCYT · Entity 2018 | Chief Scientific & Med Officer | December 06, 2022 | December 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERACYTE, INC.
Report date December 06, 2022 · Filed December 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,970 |
Reported balance
After 2022-12-06 transaction · row 1
1 source rowRow 1 · 2022-12-06 · Sale · Disposed 1,023 · Balance 65,970 F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2020 Filed Oct 7, 2020 21:06 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,500 | $35.21 | $88,025.00 |
DisclosureSEC source: 0001437749-20-020855 · rdgdoc.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,399 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 21:06 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 2,500 | $20.21 | $50,525.00 |
DisclosureSEC source: 0001437749-20-020855 · rdgdoc.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 21:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 2,937 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001437749-20-019416 · rdgdoc.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,438 Underlying: Common Stock · 2,937 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 21:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 3,542 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001437749-20-019416 · rdgdoc.xml · derivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 3,542 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 21:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,141 | $32.24 | $69,016.42 |
DisclosureSEC source: 0001437749-20-019416 · rdgdoc.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,399 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $31.78 to $32.67. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 21:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,350 | $31.21 | $73,339.27 |
DisclosureSEC source: 0001437749-20-019416 · rdgdoc.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,540 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.69 to $31.68. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 21:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,536 | $30.05 | $76,208.07 |
DisclosureSEC source: 0001437749-20-019416 · rdgdoc.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,890 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $29.58 to $30.49. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 21:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 2,937 | $5.98 | $17,563.26 |
DisclosureSEC source: 0001437749-20-019416 · rdgdoc.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 21:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 3,542 | $9.05 | $32,055.10 |
DisclosureSEC source: 0001437749-20-019416 · rdgdoc.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 21:13 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 540 | $34.16 | $18,446.40 |
DisclosureSEC source: 0001437749-20-019359 · rdgdoc.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,947 F1 · kind: The reporting person is reporting the withholding of 292 and 248 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 588 and 500 Restricted Stock Units, respectively, granted on March 2, 2018 and February 28, 2019, respectively, and does not represent a sale by the reporting person. Read SEC document |
| July 31, 2020 Filed Aug 5, 2020 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001437749-20-016560 · rdgdoc.xml · derivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 20,000 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| July 31, 2020 Filed Aug 5, 2020 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 20,000 | $35.33 | $706,694.00 |
DisclosureSEC source: 0001437749-20-016560 · rdgdoc.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,487 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $35.21 to $35.78. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| July 31, 2020 Filed Aug 5, 2020 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 20,000 | $20.21 | $404,200.00 |
DisclosureSEC source: 0001437749-20-016560 · rdgdoc.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:29 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 1,469 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001437749-20-015126 · rdgdoc.xml · derivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,375 Underlying: Common Stock · 1,469 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F7 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:29 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 1,771 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001437749-20-015126 · rdgdoc.xml · derivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,167 Underlying: Common Stock · 1,771 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:29 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 13,498 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001437749-20-015126 · rdgdoc.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 Underlying: Common Stock · 13,498 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F5 · derivative.exercise_date: The option is fully vested. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:29 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 200 | $30.46 | $6,091.00 |
DisclosureSEC source: 0001437749-20-015126 · rdgdoc.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,487 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.45 to $30.46. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:29 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 15,814 | $29.69 | $469,520.82 |
DisclosureSEC source: 0001437749-20-015126 · rdgdoc.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,687 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $29.41 to $30.38. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:29 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 724 | $28.82 | $20,865.68 |
DisclosureSEC source: 0001437749-20-015126 · rdgdoc.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,501 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.40 to $29.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:29 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 1,469 | $5.98 | $8,784.62 |
DisclosureSEC source: 0001437749-20-015126 · rdgdoc.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:29 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 1,771 | $9.05 | $16,027.55 |
DisclosureSEC source: 0001437749-20-015126 · rdgdoc.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:29 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 13,498 | $14.34 | $193,561.32 |
DisclosureSEC source: 0001437749-20-015126 · rdgdoc.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 5,312 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-20-000080 · wf-form4_159130180118115.xml · derivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,938 Underlying: Common Stock · 5,312 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,406 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-20-000080 · wf-form4_159130180118115.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,844 Underlying: Common Stock · 4,406 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 521 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001384101-20-000080 · wf-form4_159130180118115.xml · derivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 521 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F4 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 10,786 | $26.22 | $282,808.92 |
DisclosureSEC source: 0001384101-20-000080 · wf-form4_159130180118115.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,487 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.84 to $26.62. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 5,312 | $9.05 | $48,073.60 |
DisclosureSEC source: 0001384101-20-000080 · wf-form4_159130180118115.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,406 | $5.98 | $26,347.88 |
DisclosureSEC source: 0001384101-20-000080 · wf-form4_159130180118115.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 521 | $5.43 | $2,829.03 |
DisclosureSEC source: 0001384101-20-000080 · wf-form4_159130180118115.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 540 | $26.01 | $14,045.40 |
DisclosureSEC source: 0001384101-20-000080 · wf-form4_159130180118115.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,034 F1 · kind: The reporting person is reporting the withholding of 292 and 248 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587 and 500 Restricted Stock Units, respectively, granted on March 2, 2018 and February 28, 2019, respectively, and does not represent a sale by the reporting person. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 1,750 | $0.00 Strike: $26.55 | $0.00 |
DisclosureSEC source: 0001384101-20-000066 · wf-form4_158940324697521.xml · derivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires 2030-05-10 F2 · derivative.exercise_date: The stock options awarded on May 11, 2020 vest 18 months from May 1, 2020 subject to continuing employment of the Reporting Person on the vesting date. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000066 · wf-form4_158940324697521.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,574 F1 · kind: Restricted stock units awarded on May 11, 2020 vest 18 months from May 1, 2020 subject to continuing employment of the Reporting Person on the vesting date. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,407 | $5.98 Strike: $5.98 | $26,353.86 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · derivative · entry 10 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,250 Underlying: Common Stock · 4,407 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F7 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 5,313 | $9.05 Strike: $9.05 | $48,082.65 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · derivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 5,313 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F6 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 1,563 | $5.43 Strike: $5.43 | $8,487.09 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · derivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522 Underlying: Common Stock · 1,563 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F5 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $6.45 Strike: $6.45 | $24,187.50 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 Underlying: Common Stock · 3,750 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,339 | $25.91 | $60,592.03 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,274 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.78 to $26.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 30,542 | $25.35 | $774,206.10 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,613 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $24.77 to $25.75. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,407 | $5.98 | $26,353.86 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 5,313 | $9.05 | $48,082.65 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 1,563 | $5.43 | $8,487.09 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 3,750 | $6.45 | $24,187.50 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:55 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 896 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000033 · wf-form4_158327613077235.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,122 F2 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:55 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001384101-20-000033 · wf-form4_158327613077235.xml · derivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-03-27 F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:55 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000033 · wf-form4_158327613077235.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,018 F1 · kind: Restricted stock units awarded on February 28, 2020 vest 25% on March 2, 2021 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:17 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 8,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000025 · wf-form4_158275182062299.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,018 F2 · kind: The reporting person is reporting the withholding of 8,844 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 25,000 Performance Stock Units vested on February 24, 2020 and does not represent a sale by the reporting person. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:17 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000025 · wf-form4_158275182062299.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,862 F1 · kind: Represents the acquisition of restricted stock units ("RSUs") earned by the Reporting Person upon the achievement of performance goals for the one-year period ended December 31, 2019, as reflected in the financial statements certified by the Audit Committee of the Board of Directors on February 24, 2020. The RSUs vested as to 50% of the total RSUs earned on February 24, 2020, and the remaining 50% of the RSUs will vest on February 24, 2021, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 32,803 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001384101-19-000160 · wf-form4_157592610410859.xml · derivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 32,803 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 32,803 | $29.39 | $964,142.50 |
DisclosureSEC source: 0001384101-19-000160 · wf-form4_157592610410859.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,862 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $29.34 to $29.56. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 32,803 | $14.34 | $470,395.02 |
DisclosureSEC source: 0001384101-19-000160 · wf-form4_157592610410859.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.